{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:17Z","timestamp":1786987577288,"version":"build-2736575974"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Robert and Deborah First Family Fund (KME)","award":["NICHD K12HD00849"],"award-info":[{"award-number":["NICHD K12HD00849"]}]},{"name":"Saltonstall Research Fund"},{"name":"Potter Research Fund"},{"name":"Sperling Family Fund Fellowship"},{"name":"Bach Underwood Fund"},{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006800","name":"Honorable Tina Brozman Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006800","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ctrv.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T11:39:32Z","timestamp":1528717172000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction"],"prefix":"10.1016","volume":"69","author":[{"given":"Allison A.","family":"Gockley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2018.06.004_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx525","article-title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000\u20132013","author":"Oseledchyk","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ygyno.2008.01.033","article-title":"Conditional survival in ovarian cancer: results from the SEER dataset 1988\u20132001","volume":"109","author":"Choi","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"9760","key":"10.1016\/j.ctrv.2018.06.004_b0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","article-title":"Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995\u20132007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data","volume":"377","author":"Coleman","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/AOG.0000000000000534","article-title":"Can molecular diagnostics usher in a new era for screening, diagnosis, and treatment of ovarian cancer?","volume":"124","author":"Mutch","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2018.06.004_b0040","article-title":"Two large randomised trials show ovarian cancer screening has minimal impact on survival","author":"Johnson","year":"2016","journal-title":"BJOG"},{"issue":"10022","key":"10.1016\/j.ctrv.2018.06.004_b0045","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ctrv.2018.06.004_b0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"9160","key":"10.1016\/j.ctrv.2018.06.004_b0055","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ctrv.2018.06.004_b0060","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2018.06.004_b0065","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0070","article-title":"Practice bulletin No 182: hereditary breast and ovarian cancer syndrome","volume":"130","author":"Committee on Practice Bulletins-Gynecology","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"44","key":"10.1016\/j.ctrv.2018.06.004_b0080","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.ctrv.2018.06.004_b0085","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.ctrv.2018.06.004_b0090","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2018.06.004_b0095","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO.2005.05.4171","article-title":"DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes","volume":"24","author":"Kennedy","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2018.06.004_b0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","article-title":"Gynecologic cancer as a \u201csentinel cancer\u201d for women with hereditary nonpolyposis colorectal cancer syndrome","volume":"105","author":"Lu","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2018.06.004_b0110","unstructured":"Network, N.C.C. Genetic\/Familial High-Risk Assessment: Colorectal Cancer Screening Version 1.2018. 2018 [cited 2018 4\/20\/18]; Available from: <https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf>."},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ajog.2017.04.011","article-title":"Current and future role of genetic screening in gynecologic malignancies","volume":"217","author":"Ring","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"7353","key":"10.1016\/j.ctrv.2018.06.004_b0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.06.004_b0125","unstructured":"Cancer Stat Facts: Ovarian Cancer, SEER Cancer Statistics Review; 2018; Available from: <https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html>."},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/aje\/kwp314","article-title":"Risk factors for epithelial ovarian cancer by histologic subtype","volume":"171","author":"Gates","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2011.10.009","article-title":"The epidemiology of endometrial and ovarian cancer","volume":"26","author":"Cramer","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.ctrv.2018.06.004_b0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/aje\/kwv308","article-title":"Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women","volume":"183","author":"Yang","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2006.06.088","article-title":"Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies","volume":"196","author":"Pelucchi","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"9609","key":"10.1016\/j.ctrv.2018.06.004_b0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian","year":"2008","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.ctrv.2018.06.004_b0160","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.AOG.0000255664.48970.e6","article-title":"Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk","volume":"109","author":"Lurie","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/94.1.32","article-title":"Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk","volume":"94","author":"Schildkraut","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","article-title":"Pathologic findings in prophylactic oophorectomy specimens in high-risk women","volume":"87","author":"Leeper","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2018.06.004_b0185","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/PAS.0b013e31819e986a","article-title":"Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma","volume":"33","author":"Rabban","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"29","key":"10.1016\/j.ctrv.2018.06.004_b0190","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the \u2018fallopian tube hypothesis\u2019 in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.pap.0000201826.46978.e5","article-title":"Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer","volume":"13","author":"Lee","year":"2006","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0210","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/modpathol.2016.238","article-title":"Serous tubal intraepithelial neoplasia: the concept and its application","volume":"30","author":"Meserve","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0215","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2017.28.e3","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0220","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ctrv.2018.06.004_b0225","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.ctrv.2018.06.004_b0230","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0235","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2017.04.015","article-title":"Frequency of \u201cincidental\u201d serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: a six-year study","volume":"146","author":"Meserve","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2018.06.004_b0245","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/modpathol.2016.101","article-title":"CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma","volume":"29","author":"Kuhn","year":"2016","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2013evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/PAS.0b013e3181dcede7","article-title":"Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis","volume":"34","author":"Kuhn","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2011.05.021","article-title":"Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas","volume":"123","author":"Karst","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2015.07.100","article-title":"Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma","volume":"139","author":"Novak","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2013.562","article-title":"Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors","volume":"34","author":"Labidi-Galy","year":"2015","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0275","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.01.037","article-title":"Racial\/ethnic disparities in contraceptive use: variation by age and women's reproductive experiences","volume":"210","author":"Dehlendorf","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0285","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/AOG.0000000000002312","article-title":"Salpingectomy for sterilization: change in practice in a large integrated health care system, 2011\u20132016","volume":"130","author":"Powell","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/humupd\/dmq030","article-title":"Tubal ligation and the risk of ovarian cancer: review and meta-analysis","volume":"17","author":"Cibula","year":"2011","journal-title":"Hum Reprod Update"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0295","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ije\/dyt042","article-title":"Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies","volume":"42","author":"Sieh","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0300","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jmig.2016.12.004","article-title":"Operative outcomes of opportunistic bilateral salpingectomy at the time of benign hysterectomy in low-risk premenopausal women: a systematic review","volume":"24","author":"Kho","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0305","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jmig.2017.01.001","article-title":"The role of opportunistic bilateral salpingectomy vs tubal occlusion or ligation for ovarian cancer prophylaxis","volume":"24","author":"Ely","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0310","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/aogs.12516","article-title":"Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study","volume":"94","author":"Madsen","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0320","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2014.10.005","article-title":"Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma","volume":"135","author":"Lessard-Anderson","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.01.003","article-title":"Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention","volume":"210","author":"McAlpine","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.10.035","article-title":"The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States","volume":"216","author":"Hanley","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"3 Pt 2","key":"10.1016\/j.ctrv.2018.06.004_b0335","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/gme.0b013e318038d333","article-title":"Surgical menopause and cardiovascular risks","volume":"14","author":"Lobo","year":"2007","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.gme.0000218683.97338.ea","article-title":"Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis","volume":"13","author":"Atsma","year":"2006","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.ctrv.2018.06.004_b0345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0350","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.fertnstert.2013.07.1997","article-title":"Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial","volume":"100","author":"Findley","year":"2013","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0355","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ygyno.2013.03.023","article-title":"Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere","volume":"129","author":"Morelli","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0360","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/AOG.0000000000001531","article-title":"Experience with opportunistic salpingectomy in a large, community-based health system in the United States","volume":"128","author":"Garcia","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0365","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ajo.12402","article-title":"Opportunistic bilateral salpingectomy during gynaecological surgery for benign disease: a survey of current Australian practice","volume":"55","author":"Kapurubandara","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.ctrv.2018.06.004_b0370","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.3802\/jgo.2017.28.e52","article-title":"Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology","volume":"28","author":"Mikami","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jogc.2016.12.005","article-title":"No. 344-Opportunistic salpingectomy and other methods of risk reduction for ovarian\/fallopian tube\/peritoneal cancer in the general population","volume":"39","author":"Salvador","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"10.1016\/j.ctrv.2018.06.004_b0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/07357907.2016.1242597","article-title":"Physicians' perspectives and practice patterns toward opportunistic salpingectomy in high- and low-risk women","volume":"35","author":"Jones","year":"2017","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0385","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/AOG.0000000000001350","article-title":"ACOG Committee opinion No. 660 summary: family building through gestational surrogacy","volume":"127","author":"American College of","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/AOG.0000000000000630","article-title":"Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy","volume":"125","author":"Kwon","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ctrv.2018.06.004_b0395","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1471-0528.13742","article-title":"Opportunistic salpingectomy at benign gynaecological surgery for ovarian cancer prevention should be performed within a clinical trial: AGAINST: can we afford to wait for the results?","volume":"123","author":"Kehoe","year":"2016","journal-title":"BJOG"},{"issue":"12","key":"10.1016\/j.ctrv.2018.06.004_b0400","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0405","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0410","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ctrv.2018.06.004_b0415","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.ctrv.2018.06.004_b0420","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.06.004_b0425","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2014.00021","article-title":"Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review","volume":"4","author":"Schenberg","year":"2014","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.06.004_b0430","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2014.02.030","article-title":"Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers","volume":"133","author":"Holman","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2018.06.004_b0435","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-015-1597-y","article-title":"Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study","volume":"15","author":"Harmsen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2018.06.004_b0440","unstructured":"Center MAC. WISP: women choosing surgical prevention; 2017 [cited 2017 October 8, 2017]; Available from: <https:\/\/wisp.mdanderson.org\/>."},{"key":"10.1016\/j.ctrv.2018.06.004_b0445","unstructured":"Medicine USNLO. NCT019077; 2017 August 22, 2017 [cited 2017 October 8, 2017]; Available from: <https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01907789?term=NCT01907789&rank=1>."},{"key":"10.1016\/j.ctrv.2018.06.004_b0450","unstructured":"Medicine USNLO. NCT01608074; 2017 July 21, 2017 [cited 2017 October 8, 2017]; Available from: <https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01608074?term=NCT01608074&rank=1>."},{"issue":"5","key":"10.1016\/j.ctrv.2018.06.004_b0455","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s10897-017-0090-y","article-title":"Impact of panel gene testing for hereditary breast and ovarian cancer on patients","volume":"26","author":"Lumish","year":"2017","journal-title":"J Genet Couns"},{"issue":"12","key":"10.1016\/j.ctrv.2018.06.004_b0460","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/GIM.0b013e318226fc15","article-title":"Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions","volume":"13","author":"Murray","year":"2011","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.ctrv.2018.06.004_b0465","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2018.06.004_b0470","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/gim.2014.48","article-title":"Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations","volume":"16","author":"Garcia","year":"2014","journal-title":"Genet Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T19:03:16Z","timestamp":1536692596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":94,"alternative-id":["S0305737218300987"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}